Pfizer Inc. vs Galapagos NV: SG&A Expense Trends

SG&A Expense Trends: Pfizer Inc. vs Galapagos NV

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Pfizer Inc. and Galapagos NV have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust market position and strategic cost management.

Conversely, Galapagos NV has shown a more dynamic pattern. Starting with modest expenses in 2014, the company experienced a significant surge, peaking in 2022 with a 2,500% increase compared to 2014. This growth underscores Galapagos' aggressive expansion and investment in R&D. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic priorities of these industry giants.